Proteases as activators for cytotoxic prodrugs in antitumor therapy.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Genomics & Proteomics

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 24709544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody Drug Conjugates for Cancer Therapy

  2016cited by this paper
• Improving the Therapeutic Potential of Human Granzyme B for Targeted Cancer Therapy

  2013cited by this paper
• Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu

  2013cited by this paper
• Selective Induction of Cancer Cell Death by Targeted Granzyme B

  2013cited by this paper
• Antibody-drug conjugate (ADC) clinical pipeline: a review.

  2013cited by this paper
• Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets

  2013cited by this paper
• Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

  2013cited by this paper
• Implementing personalized cancer genomics in clinical trials

  2013cited by this paper
• Targeted therapies: how personal should we go?

  2012cited by this paper
• Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

  2012cited by this paper
• Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.

  2012cited by this paper
• Design of human granzyme B variants resistant to serpin B9

  2012cited by this paper
• The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

  2012cited by this paper
• Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

  2012cited by this paper
• Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

  2012cited by this paper
• Imaging a functional tumorigenic biomarker in the transformed epithelium

  2012cited by this paper
• Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein.

  2012cited by this paper
• Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

  2012cited by this paper
• Protease-Activated Drug Development

  2012cited by this paper
• Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing

  2012cited by this paper
• Engineering Enzymatically Activated “Molecular Grenades” for Cancer

  2012cited by this paper
• The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer

  2012cited by this paper
• Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon.

  2012cited by this paper
• In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

  2011cited by this paper
• Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.

  2011cited by this paper
• Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy.

  2011cited by this paper
• Antibody-enzyme fusion proteins for cancer therapy.

  2011cited by this paper
• Prostate-Specific Membrane Antigen-Based Therapeutics

  2011cited by this paper
• The next generation of antibody-drug conjugates comes of age.

  2010cited by this paper
• Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier

  2010cited by this paper
• Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity.

  2010cited by this paper
• Delivery and therapeutic potential of human granzyme B

  2010cited by this paper
• Toxin-Based Therapeutic Approaches

  2010cited by this paper
• Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome‐specific and proteolytically released protein

  2010cited by this paper
• Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  2010cited by this paper
• Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

  2010cited by this paper
• Chronic DLL4 blockade induces vascular neoplasms

  2010cited by this paper
• Therapeutic antibody targeting of individual Notch receptors

  2010cited by this paper
• The safety and side effects of monoclonal antibodies

  2010cited by this paper
• Hepatocyte growth factor activation inhibitors - therapeutic potential in cancer.

  2010cited by this paper
• Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions.

  2009cited by this paper
• Personalized cancer therapy gets closer

  2009cited by this paper
• A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.

  2009cited by this paper
• Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

  2009cited by this paper
• The urokinase receptor as an entertainer of signal transduction.

  2009cited by this paper
• Improved immunotoxins with novel functional elements.

  2009cited by this paper
• Antibody-Drug Conjugates for Cancer Therapy

  2008cited by this paper
• Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition.

  2008cited by this paper
• Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

  2008cited by this paper
• Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides.

  2008cited by this paper
• Cardiac toxicity of ErbB2-targeted therapies: what do we know?

  2008cited by this paper
• Cathepsin D--many functions of one aspartic protease.

  2008cited by this paper
• On the edge of validation--cancer protease fibroblast activation protein.

  2008cited by this paper
• The ADAMs: signalling scissors in the tumour microenvironment

  2008cited by this paper
• Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis

  2008cited by this paper
• Small Cleavable Adapters Enhance the Specific Cytotoxicity of a Humanized Immunotoxin Directed Against CD64-positive Cells

  2008cited by this paper
• In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases

  2007cited by this paper
• A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.

  2007cited by this paper
• A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice.

  2007cited by this paper
• Matrix metalloproteases: Underutilized targets for drug delivery

  2007cited by this paper
• Mechanisms of adverse effects of anti-VEGF therapy for cancer

  2007cited by this paper
• Emerging roles of proteases in tumour suppression

  2007cited by this paper
• Activation of CD95L fusion protein prodrugs by tumor-associated proteases

  2007cited by this paper
• A Novel Biomarker for Staging Human Prostate Adenocarcinoma: Overexpression of Matriptase with Concomitant Loss of its Inhibitor, Hepatocyte Growth Factor Activator Inhibitor-1

  2006cited by this paper
• Cysteine cathepsins: multifunctional enzymes in cancer

  2006cited by this paper
• Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer–drug conjugate

  2006cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

  2006cited by this paper
• Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

  2006cited by this paper
• Semisynthetic maytansine analogues for the targeted treatment of cancer.

  2006cited by this paper
• Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug

  2006cited by this paper
• A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug

  2006cited by this paper
• Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface

  2006cited by this paper
• Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

  2006cited by this paper
• Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.

  2005cited by this paper
• A Closer Look at Protein Transduction Domains as a Tool in Drug Delivery

  2005cited by this paper
• Overcoming the immunologic response to foreign enzymes in cancer therapy

  2005cited by this paper
• Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy.

  2005cited by this paper
• Tumor therapeutics by design: targeting and activation of death receptors.

  2005cited by this paper
• Cationic Sites on Granzyme B Contribute to Cytotoxicity by Promoting Its Uptake into Target Cells

  2005cited by this paper
• Expression of prostate‐specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues

  2005cited by this paper
• Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

  2005cited by this paper
• Protein cargo delivery properties of cell-penetrating peptides. A comparative study.

  2004cited by this paper
• Killing of target cells by redirected granzyme B in the absence of perforin

  2004cited by this paper
• Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas

  2004cited by this paper
• A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo.

  2003cited by this paper
• Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein.

  2003cited by this paper
• Anthrax toxin: structures, functions and tumour targeting

  2003cited by this paper
• Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease–substrate interaction

  2003cited by this paper
• Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies.

  2003cited by this paper
• Regulation of apoptosis by endoplasmic reticulum pathways

  2003cited by this paper
• A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins

  2003cited by this paper
• Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

  2003cited by this paper
• Anthrax toxin triggers endocytosis of its receptor via a lipid raft–mediated clathrin-dependent process

  2003cited by this paper
• TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor

  2002cited by this paper
• Strategies for MMP inhibition in cancer: innovations for the post-trial era

  2002cited by this paper
• Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase

  2002cited by this paper
• Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

  2002cited by this paper
• uPAR: a versatile signalling orchestrator

  2002cited by this paper
• Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

  2002cited by this paper

• Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

  2026cites this paper
• Tumour-specific STING agonist synthesis via a two-component prodrug system

  2025cites this paper
• Enhanced drug delivery in cancer therapy: role of TMPRSS4 protease in liposomal engineering

  2025cites this paper
• Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

  2024cites this paper
• Using Potential Years of Life Lost (PYLL) to Compare Premature Mortality between Romanian Counties to Confirmed COVID-19 Cases in 2020 and 2021

  2024cites this paper
• Stimuli-responsive prodrugs with self-immolative linker for improved cancer therapy.

  2024cites this paper
• Exploration of the antibody–drug conjugate clinical landscape

  2023cites this paper
• Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas

  2022cites this paper
• Platform to Discover Protease-Activated Antibiotics and Application to Siderophore–Antibiotic Conjugates

  2021cites this paper
• The effects of chicken egg white cystatin and proteinase inhibitor on cysteine peptidase-like activity in the sera of patients with breast cancer.

  2021cites this paper
• Platform to Discover Protease-Activated Antibiotics and Application to Siderophore-Antibiotic Conjugates.

  2020cites this paper
• Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment

  2020cites this paper
• Cysteine cathepsins as therapeutic targets in inflammatory diseases

  2020cites this paper
• Tumor-suppressive proteases revisited: Role in inhibiting tumor progression and metastasis

  2020cites this paper
• Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.

  2020cites this paper
• Protease‐activated prodrugs: strategies, challenges, and future directions

  2020cites this paper
• Coumarin as a structural component of substrates and probes for serine and cysteine proteases

  2020cites this paper
• Proteolysis and oxidation of therapeutic proteins after intradermal or subcutaneous administration.

  2020cites this paper
• G-Protein Coupled Receptors in Cancer and Targeting Strategies

  2019cites this paper
• Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

  2019cites this paper
• Cancer targeting peptides

  2019cites this paper
• The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation

  2019cites this paper
• Prodrug Activation by a Viral Protease: Evaluating Combretastatin Peptide Hybrids To Selectively Target Infected Cells.

  2019cites this paper
• The role of proteases in epithelial-to-mesenchymal cell transitions in cancer

  2019cites this paper
• The expanding role of prodrugs in contemporary drug design and development

  2018cites this paper
• Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

  2018cites this paper
• Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib

  2018cites this paper
• Multiscale Methods in Drug Design Bridge Chemical and Biological Complexity in the Search for Cures.

  2018cites this paper
• Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.

  2017cites this paper
• Catabolism of antibody drug conjugates and characterization methods.

  2017cites this paper
• In vivo near-infrared imaging and phototherapy of tumors using a cathepsin B-activated fluorescent probe.

  2017cites this paper
• Matrix‐metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression

  2017cites this paper
• Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination

  2017cites this paper
• Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

  2016cites this paper
• Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents.

  2016cites this paper
• Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery.

  2016cites this paper
• A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.

  2016cites this paper
• Proteases in cancer drug delivery.

  2016cites this paper
• Non-cytochrome P450-mediated bioactivation and its toxicological relevance

  2016cites this paper
• Spectroscopic and molecular modelling investigations of supramolecular complex of β-cyclodextrin with N-[(4-sulfonamidophenyl)ethyl]-5-(1,2-dithiolan-3-yl)pentanamide

  2016cites this paper
• Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden

  2015cites this paper
• Targeting Carbonic Anhydrase IX Activity and Expression

  2015cites this paper
• Effect of attachment site on stability of cleavable antibody drug conjugates.

  2015cites this paper
• Design, synthesis, and functional evaluation of CO-releasing molecules triggered by Penicillin G amidase as a model protease.

  2015cites this paper
• Targeting thapsigargin towards tumors.

  2015cites this paper
• Design, Synthese und funktionelle Evaluierung von CO‐freisetzenden Molekülen, die durch Penicillin‐G‐Amidase als Modellprotease aktiviert werden

  2015cites this paper
• Anticancer drugs induce hypomethylation of the acetylcholinesterase promoter via a phosphorylated-p38-DNMT1-AChE pathway in apoptotic hepatocellular carcinoma cells.

  2015cites this paper
• Protein engineering: a new frontier for biological therapeutics.

  2015cites this paper
• Molecular imaging of the tumor microenvironment for precision medicine and theranostics.

  2014cites this paper
• Betydningen av legumain og cystatin E/M for aktivering av caspase-3

  2014cites this paper
• Pericellular proteolysis in cancer

  2014cites this paper